Print this page
-
A Randomized, Open-Label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-Sided Colorectal Cancer.
Protocol: 072405Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized, Open-Label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-Sided Colorectal Cancer.
Protocol: 072405Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer.
Protocol: 072503Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer.
Protocol: 072503Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.
Protocol: 072504Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Breast
Colon
Esophagus
Larynx
Lip, Oral Cavity and Pharynx
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach -
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.
Protocol: 072504Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Breast
Colon
Esophagus
Larynx
Lip, Oral Cavity and Pharynx
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach -
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer.
Protocol: 072505Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer.
Protocol: 072505Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Protocol: 072602Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Protocol: 072602Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma.
Protocol: 072604Principal Investigator:
- Prateek Gulhati
Applicable Disease Sites: Colon -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma.
Protocol: 072604Principal Investigator:
- Prateek Gulhati
Applicable Disease Sites: Colon -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
- Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
Tracking Health and Resilience in Metastatic Colorectal Cancer: THRIVE-MCRC
Protocol: 132314Principal Investigator:
- Lisa Paddock
Applicable Disease Sites: Colon